|
|||||
|
|
The Safety of available immunotherapy for the treatment of glioblastoma |
|
| Authors: | S Harrison Farber Aladine A Elsamadicy Ahmet Fatih Atik Carter M Suryadevara Pakawat Chongsathidkiet Peter E Fecci |
| Institution: | 1. Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA;2. The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA;3. Department of Pathology, Duke University Medical Center, Durham, NC, USA |
| Abstract: | Introduction: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Current standard of care involves maximal surgical resection combined with adjuvant chemoradiation. Growing support exists for a role of immunotherapy in treating these tumors with the goal of targeted cytotoxicity. Here we review data on the safety for current immunotherapies being tested in GBM. Areas covered: Safety data from published clinical trials, including ongoing clinical trials were reviewed. Immunotherapeutic classes currently under investigation in GBM include various vaccination strategies, adoptive T cell immunotherapy, immune checkpoint blockade, monoclonal antibodies, and cytokine therapies. Trials include children, adolescents, and adults with either primary or recurrent GBM. Expert opinion: Based on the reviewed clinical trials, the current immunotherapies targeting GBM are safe and well-tolerated with minimal toxicities which should be noted. However, the gains in patient survival have been modest. A safe and well-tolerated combinatory immunotherapeutic approach may be essential for optimal efficacy towards GBM. |
| Keywords: | Glioblastoma immunotherapy clinical trials safety adverse events |